** Shares of drug developer Fresh Tracks Therapeutics
FRTX.O jump ~52% to $2.77 before the bell
** Says lead drug FRTX-02 met main goals of an early-stage
study
** Board also approves plan to explore strategic options to
further develop the drug
** FRTX-02 was generally safe and well tolerated within the
potential therapeutic dose range - company
** Says data supports development of the drug as a
once-daily oral treatment for atopic dermatitis and other
autoimmune and inflammatory conditions
** Study was testing different dosing regimens of FRTX-02
capsules in healthy adult subjects, as well as patients with
atopic dermatitis
** As of last close, FRTX up 22% so far this year
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))